Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TULY (rasburicase) for Malignancy-associated Hyperuricemia
NCT00921375Phase 3Completed
- Sponsor
- Virchow Group
- Start
- Feb 2010
- Primary completion
- Dec 2011
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rasburicase in hyperuricemia, sponsored by Virchow Group. Primary endpoint: Percentage of reduction in plasma uric acid at 4 hours. Started Feb 2010; status: completed.
02
Drugs
rasburicase
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT00921375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921375.